{
    "clinical_study": {
        "@rank": "67369", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.   Assess the efficacy and safety of antenatal administration of thyrotropin-releasing\n      hormone to women in premature labor to improve pulmonary outcomes in preterm infants."
        }, 
        "brief_title": "Study of Antenatal Thyrotropin-Releasing Hormone in Women in Premature Labor to Prevent Lung Disease in Preterm Infants", 
        "completion_date": "June 1998", 
        "condition": "Respiratory Distress Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Respiratory Distress Syndrome, Newborn", 
                "Respiratory Distress Syndrome, Adult"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double blind, multicenter study.  Patients are\n      randomized to receive antenatal thyrotropin-releasing hormone or placebo.\n\n      Patients receive thyrotropin-releasing hormone or placebo intravenously over 20 minutes\n      every 8 hours for 4 doses.\n\n      Infants are assessed for survival and chronic lung disease until day 28 after birth, and\n      again at 36 postmenstrual weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Pregnant women in active labor with 24-29 weeks gestation\n\n          -  Not eligible if any of the following is present: Bleeding Infection Hypertension\n             (greater than 140/90 mmHg) Fetus with hydrops or life-threatening anomalies One dead\n             fetus in multiple pregnancy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "36 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": "996", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004840", 
            "org_study_id": "199/13784", 
            "secondary_id": "CHP-5R01HD29201-03"
        }, 
        "intervention": {
            "intervention_name": "thyrotropin-releasing hormone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Hormones", 
                "Thyrotropin-Releasing Hormone"
            ]
        }, 
        "keyword": [
            "cardiovascular and respiratory diseases", 
            "neonatal disorders", 
            "rare disease", 
            "respiratory distress syndrome"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Children's Hospital of Philadelphia", 
            "last_name": "Roberta A. Ballard", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004840"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "Children's Hospital of Philadelphia", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "May 1998", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 1998"
    }, 
    "geocoordinates": {}
}